Merck KGaA’s Tepmetko Launches in China, Expanding Access to MET Inhibitor for Lung Cancer Patients
Merck KGaA (NYSE: MRK), a leading German science and technology company, has announced the commercial...
Company
Chia Tai Tianqing and Fudan University Shanghai Cancer Center Join Forces for Innovative Drug Development
Chia Tai Tianqing, a China-based pharmaceutical company, has entered into a strategic partnership with Fudan...
Takeda Secures Rights to Protagonist Therapeutics’ Rusfertide in Landmark Deal
Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced a significant expansion of its hematology portfolio...
Shanghai Junshi Biosciences’ Toripalimab Aims for Singapore Approval in Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
Novo Nordisk Delivers Strong 2023 Results with Record-Breaking Sales
Novo Nordisk A/S (NYSE: NVO), a Denmark-based pharmaceutical company, has announced its financial results for...
Sanofi Reports Full-Year Revenue Growth Driven by Dupixent and Vaccines, Eyes Biopharma Focus
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its financial report for the...
Takeda Reports Flat 9-Month Revenue Growth Amid Pipeline Optimization Efforts
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has released its financial results for the...
Merck Q4 Sales Grow 6% YOY, Driven by Pharmaceutical Segment and HPV Vaccine Demand
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has released its...
Sanofi Secures Rights to Graviton’s ROCK2 Inhibitor Candidates in Strategic Biotechnology Investment
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has made an undisclosed investment in biotechnology...
WuXi Biologics Achieves Full-Scale Manufacturing Milestone at Ireland Facility
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
HitGen Inc. and Bostal Drug Delivery Form Strategic Partnership to Advance Nucleic Acid Drug Development
HitGen Inc. (SHA: 688222), a China-based company, has announced a strategic partnership with Bostal Drug...
Novartis and Fudan University Shanghai Cancer Center Renew Partnership to Drive Precision Cancer Treatments
Novartis (NYSE: NVS), the Swiss pharmaceutical colossus, has renewed its memorandum of understanding with Fudan...
Rebecca Tech Secures USD 10 Million in Series A++ Funding to Expand Micro RF Technology Globally
Rebecca Tech LLC, a Hangzhou-based manufacturer specializing in microelectromechanical RF (radiofrequency) technology, has announced the...
Jiangsu Hengrui Receives Chinese Approval for First Domestic Category 1 Opioid Analgesic for Postoperative Pain
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has proclaimed the receipt of marketing approval in...
Acotec Scientific’s Peridge Catheter Receives NMPA Nod for Hemodialysis Lesion Treatment
Acotec Scientific Holdings Ltd (HKG: 6669), a China-based medical device company, has announced that it...
Beijing Tiantan Biological Halts Phase III Clinical Trial for CMV Immunoglobulin Citing Strategic Reasons
Beijing Tiantan Biological Products Co., Ltd (SHA: 600161), a biopharmaceutical firm based in China, has...
WuXi XDC Forecasts Over 100% Revenue Growth for 2023 on Strength of ADC Industry
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKEX: 2269) and WuXi STA,...
GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth...
Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, reported a substantial leap in its global sales...
Gilead’s Kite Subsidiary Reduces CAR T-Cell Therapy Turnaround Time with FDA Approval
Kite, a subsidiary of Gilead (NASDAQ: GILD), has announced a significant enhancement in the treatment...